A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity data
Abstract Vaccine efficacy is often assessed by counting disease cases in a clinical trial. A new quantitative framework proposed here (“PoDBAY,” Probability of Disease Bayesian Analysis), estimates vaccine efficacy (and confidence interval) using immune response biomarker data collected shortly afte...
Main Authors: | Julie Dudášová, Regina Laube, Chandni Valiathan, Matthew C. Wiener, Ferdous Gheyas, Pavel Fišer, Justina Ivanauskaite, Frank Liu, Jeffrey R. Sachs |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-11-01
|
Series: | npj Vaccines |
Online Access: | https://doi.org/10.1038/s41541-021-00377-6 |
Similar Items
-
Replicate Testing of Clinical Endpoints Can Prevent No-Go Decisions for Beneficial Vaccines
by: Daniel I. S. Rosenbloom, et al.
Published: (2023-09-01) -
Micronutrients to Support Vaccine Immunogenicity and Efficacy
by: Philip C. Calder, et al.
Published: (2022-04-01) -
Identifying a transcriptional signature for cell sensitivity to the cancer chemotherapy agent, BCNU
by: Valiathan, Chandni Rajan
Published: (2011) -
Predictive Markers of Immunogenicity and Efficacy for Human Vaccines
by: Matthieu Van Tilbeurgh, et al.
Published: (2021-06-01) -
Immunogenicity and Efficacy Evaluation of Subunit Astrovirus Vaccines
by: Mehdi R.M. Bidokhti, et al.
Published: (2019-08-01)